Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5651326 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL1535294 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL4778591 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL581065 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL514304 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL5168130 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL741996 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL4773208 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL2805480 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL2285354 | 0.98 | DUT (0.37) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| WO-2026107227-A1 | COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12590108-B2 | Boracic acid compound | PHAENO THERAPEUTICS CO., LTD (CN) | 2026-03-31 | — | — | US | disclosed |
| EP-4695241-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | Danatlas Pharmaceuticals Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-20260034113-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| US-20250367129-A1 | Lipid Compounds and Uses Thereof | PFIZER (US) | 2025-12-04 | — | — | US | disclosed |
| US-12479838-B2 | D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20050186580-A1 | Quality control method for array manufacture | AGILENT TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | disclosed |
| US-20050186579-A1 | MALDI-MS analysis of nucleic acids bound to a surface | AGILENT TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | disclosed |
| US-20050048601-A1 | Method for polynucleotide synthesis | REGENTS OF THE UNIVERSITY OF COLORADO, THE | 2005-03-03 | — | — | US | disclosed |
| US-20050048496-A1 | Method of polynucleotide synthesis using modified support | AGILENT TECHNOLOGIES, INC. | 2005-03-03 | — | — | US | disclosed |
| US-20050048497-A1 | Cleavable linker for polynucleotide synthesis | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2005-03-03 | — | — | US | disclosed |
| EP-1510522-A1 | Method of polynucleotide synthesis using modified support | Agilent Technologies Inc (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6710048-B2 | SELECTIVE INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE; TO TREAT SOLID-TUMOR CANCERS, ANGIOGENESIS, DIABETIC RETINOPATHY, RHEUMATOID ARTHRITIS, ENDOMETRIOSIS AND PSORIASIS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-03-23 | — | — | US | disclosed |
| EP-1330452-A2 | PYRAZINE DERIVATIVES AS MODULATORS OF TYROSINE KINASES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030060629-A1 | Pyrazine derivatives as modulators of tyrosine kinases | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2002024681-A2 | PYRAZINE DERIVATIVES AS MODULATORS OF TYROSINE KINASES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | DUT 1465/4885 |
| US-20050048496-A1 | Method of polynucleotide synthesis using modified support | POLN, POLRMT, POLM | DUT 30/4885 |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR5A2, NR3C1 | DUT 718/4885 |
| US-12479838-B2 | D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof | DRD3, ADRB3, VDR | DUT 1979/4885 |
| US-20050048601-A1 | Method for polynucleotide synthesis | POLN, RNGTT, NSUN2 | DUT 29/4885 |
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | AADAC, PAICS, CYP3A43 | DUT 167/4885 |
| US-12590108-B2 | Boracic acid compound | ME1, GPBAR1, BCL6 | DUT 3797/4885 |
| US-20260034113-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | SRD5A2, NR3C2, SRD5A1 | DUT 736/4885 |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | DUT 1822/4885 |
| US-20050048497-A1 | Cleavable linker for polynucleotide synthesis | TYMP, POLN, CPSF1 | DUT 11/4885 |
| US-20030060629-A1 | Pyrazine derivatives as modulators of tyrosine kinases | FLT1, FLT4, KDR | DUT 3589/4885 |
| US-20250367129-A1 | Lipid Compounds and Uses Thereof | POLN, PHOSPHO1, NPC1 | DUT 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.